ESMO 2022 on the Phase 3 RATIONALE-301 Study: Tislelizumab OS Benefit vs. Sorafenib as 1L Treatment for Unresectable HCC

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

ecancer

ecancer.org

ecancer is a UK charity which provides accessible, high-quality educational content, free to the global oncology community. Our mission is to raise the standards of care for cancer patients across the world through education.

ELCC 2024
EAU 2024
ASCO GU 2024
ASCO GI 2024
AORTIC 2023
ASH 2023
SABCS 2023
ESMO 2023
Common Sense Oncology
WCLC 2023
ESMO WCGIC 2023
ASCO® 2023
EHA® 2023
ELCC 2023
ASCO GU 2023
BGICC 2023
ASCO GI 2023
SABCS 2022
ESMO 2022
WCLC 2022
EHA 2022
ASCO 2022
ASCO 2021
Lymphoma
Leukemia
Myeloma
GYN Cancers
Head&Neck Cancers
GI Cancers
Breast Cancers
GU Cancers
Lung Cancers
Skin Cancers
Basic Science
Supportive & Palliative Care
Business
Events

Playback speed

10 seconds

ESMO 2022 on the Phase 3 RATIONALE-301 Study: Tislelizumab OS Benefit vs. Sorafenib as 1L Treatment for Unresectable HCC

By ecancer FEATURING Richard S. Finn

27 views

September 30, 2022

0 Comments

Management Strategies for Anemia in First-line Maintenance Therapy f…

Feat. D. Czel, C. Arn

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam

ESMO 2022